文献速递临床试验与 GCP

三伏贴穴位贴敷治疗支气管哮喘:随机对照试验研究方案

Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-07-29

本研究为多中心、双盲、平行、随机、安慰剂对照临床试验,计划纳入72例慢性持续期或临床缓解期支气管哮喘患者,随机分为三伏贴组和安慰剂组,每组接受3次治疗。主要结局为3次治疗后第1秒用力呼气容积变化,次要结局包括生活质量、哮喘控制及血尿生物标志物。旨在明确三伏贴的临床疗效与安全性。

要点

  • 三伏贴治疗支气管哮喘的疗效与安全性尚缺乏高质量证据。
  • 试验采用双盲、随机、安慰剂对照设计,计划纳入72例患者。
  • 主要结局为3次治疗后FEV1变化,随访至24周。

核心结论

  • 本试验旨在明确三伏贴治疗慢性持续期或临床缓解期支气管哮喘是否优于安慰剂,并探索其抗炎与解痉机制。

研究设计与样本

  • 多中心、双盲、平行、随机、安慰剂对照临床试验,在中国4家医院开展,计划纳入72例合格受试者。
  • 受试者随机分为三伏贴组和安慰剂组,每组接受3次治疗。

关键数值与推荐

  • 主要结局为3次治疗后第1秒用力呼气容积(FEV1)变化。
  • 次要结局包括哮喘生活质量问卷、哮喘控制测试、哮喘长期随访量表评分。
  • 次要结局包括血和尿中金属硫蛋白-2与转胶蛋白-2水平。
  • 次要结局包括血中IL-5、IL-13、IL-23、IL-25及胸腺基质淋巴细胞生成素水平。
  • 数据分析在基线、第2次和第3次治疗结束时及24周随访时进行,每次治疗时评估安全性。

临床怎么用

  • 若试验证实有效,三伏贴可作为支气管哮喘的辅助非药物疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchial asthma is one of the most common inflammatory airway disorders. As one of the main non-drug therapies, the Sanfu herbal patch (SHP) has been widely used to treat bronchial asthma, although the evidence for its efficacy and associated mechanism are inconclusive. The objective of this trial is to clarify the clinical efficacy and safety of the SHP in the treatment of bronchial asthma in the chronic persistent or clinical remission stage and to provide high-quality data for further research. METHODS: We propose a multicentre, double-blinded, parallel, randomized, placebo-controlled clinical trial involving 4 study hospitals in China. A total of 72 eligible participants will be randomized into an SHP group and a placebo group. They will receive an SHP for 3 treatment sessions. The primary outcome will be changes in forced expiratory volume in 1 s after 3 treatment sessions. Secondary outcomes will include the following: (1) the Asthma Quality of Life Questionnaire, Asthma Control Test, and Asthma Long-term Follow-up Scale; (2) levels of Metallothionein-2 and Transgelin-2 in blood and urine; and (3) levels of IL-5, IL-13, IL-23, IL-25, and thymic stromal lymphopoietin in blood. Analysis of the data will be performed at baseline, at the end of the 2nd and 3rd treatment sessions, and at the 24-week follow-up. The safety of the SHP will be evaluated at each treatment session. DISCUSSION: The aims of this trial are to determine whether the SHP is more effective than placebo in the treatment of patients with bronchial asthma, as well as whether the SHP works by reducing airway inflammation and reversing bronchoconstriction. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( http://www.chictr.org.cn ), ChiCTR1900024616. Registered on 19 July 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xie X, Xu D, Zhuang L, et al. Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32727619. doi:10.1186/s13063-020-04604-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。